About
Ligo Biosciences is a San Francisco AI biotech (Y Combinator S24) building generative deep-learning models to design novel industrial enzymes, replacing slow and costly directed evolution for the chemical, pharmaceutical, agricultural and consumer-chemicals industries.
Capital graph
Founders / team· 3
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Ligo Biosciences
Ligo Biosciences is a San Francisco AI biotech (Y Combinator S24) building generative deep-learning models to design novel industrial enzymes, replacing slow and costly directed evolution for the chemical, pharmaceutical, agricultural and consumer-chemicals industries.
$500K
$500K
United States
BusinessLatest roundTotal raisedDate- Profluent
Develops generative AI and foundation models for protein design (ProGen3, E1, OpenCRISPR, etc.)
Undisclosed · $141M · 2025-11
$141M - Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M - Enveda Biosciences
Discovers naturally derived drugs from plants and microbes using its in-house AI foundation model PRISM; three oral drug candidates have entered clinical trials
Series D+ · $845M · 2026-09 · Valuation $2.0B
$845MValuation $2.0B
China
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDateOther / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.